Renal function decline and heart failure hospitalisation in patients with type 2 diabetes: dynamic predictions from the prospective SURDIAGENE cohort
Dantan E, Pailler M, Ragot S, et al.
Diabetes Res Clin Pract. 2022;110152.
Leggi
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Inzucchi SE, Claggett BL, Vaduganathan M, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00308-4.
Leggi
Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status
Gerstein HC, Sattar N
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00313-8.
Leggi
Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia
Rhou YJJ, Hor A, Wang M, et al.
Diabetes Res Clin Pract. 2022;110151.
Leggi
Terapia insulinica e inerzia. Intelligenza artificiale come driver di cambiamento – Bologna 2/3 dicembre 2022
Carissimi Soci, prosegue l’impegno AMD nell’ambito dell’Intelligenza Artificiale con una nuova iniziativa formativa. Scopo del presente progetto è quello di approfondire l’inerzia terapeutica in ogni fase del percorso di cura per indagare ulteriormente le motivazioni alla base del fenomeno. Il Convegno sarà pertanto incentrato sui seguenti obiettivi: aumentare la consapevolezza…
Leggi
Evaluation of continuous glucose monitoring-derived person-specific HbA1c in the presence and absence of complications in type 1 diabetes
Xu Y, Oriot P, Dunn TC, et al.
Diabetes Obes Metab. 2022;24(12):2383-2390.
Leggi
Progressive acceleration of insulin exposure over seven days of infusion set wear
Kastner JR, Bailey TS, Strange P, et al.
Diabetes Technol Ther. Pub. online 7 Nov 2022.
Leggi
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months
Guerci B, Giorgino F, Sapin H, et al.
Diabetes Obes Metab. 2022;24(12):2373-2382.
Leggi
Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort
Dal Canto E, Elders PJM, van der Heijden AA, et al.
Diabetologia. Pub. online 8 Nov 2022.
Leggi
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial
Succurro E ,Vizza P, Papa, et al.
Diabetes Obes Metab. 2022;24(12):2319-2330.
Leggi